Reduced insulin growth factor I concentrations in iron-overloaded β thalassaemic patients with normal growth hormone secretion and liver function

Pediatric Endocrinology Reviews

Volumn 2, Issue SUPPL. 2, 2004, Pages 256-258

  Karamifar, Hamdollah ^a   Karimi, Mehran ^b   Amirhakimi, Gholamhossein ^a   Sharbatialaei, Mohammadreza ^a   De Sanctis, Vincenzo ^c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c S ANNA HOSPITAL   (Italy)

Author keywords

Growth hormone; Partial growth hormone insensitivity; Thalassaemia

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN; SOMATOMEDIN I; UNCLASSIFIED DRUG;

ADOLESCENT; BETA THALASSEMIA; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; GROWTH RATE; HORMONE RELEASE; HORMONE RESISTANCE; HUMAN; IRAN; IRON OVERLOAD; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; NEUROSECRETION; PROVOCATION TEST; SCHOOL CHILD; SHORT STATURE;

ADOLESCENT; ALANINE TRANSAMINASE; BETA-THALASSEMIA; BODY HEIGHT; CHILD; CHILD, PRESCHOOL; DEFEROXAMINE; FEMALE; FERRITINS; HUMAN GROWTH HORMONE; HUMANS; INFANT; INSULIN-LIKE GROWTH FACTOR I; IRON OVERLOAD; LIVER; MALE;

EID: 12544256133     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Le Roith D. Insulin growth factors. N Engl J Med 1997;9:633-640
2. Saenger P, Schwartz E, Markenson AL, Graziano JH, Levi New MI, Hilgartner MW. Depressed serum somatomedin activity in β thalassaemia. J Pediatr 1980;96:214-218
3. Herington AC, Werther GA, Matthews RN, Burger HGH. Studies on the possible mechanism for deficiency of non-suppressible insulin-like activity in thalassaemia major. J Clin Endocrinol Metab 1981; 52: 393-398
4. Roth C, Pekrun A, Bartz M, Jarry H, Eber S, Lakonek M, Schroter W. Short stature and failure of pubertal development in thalassaemia major: evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotrophin secretion. Eur J Pediatr 1997; 156:777-783
5. Chrisis DC, Alexandrides TK, Koromantzou E, Georgopoulos K, Vassilakos P, Kiess W, Kratsch J, Benatis N, Spiliotis BE. Novel application of IGF-I and IGFBP3 generation tests in the diagnosis of growth hormone axis disturbances in children with β thalassaemia. Clin Endocrinol 2001;54:253-259
6. Spiliotis B. β-thalassaemia and normal growth: are they compatible? Eur J Endocrinol 1998; 139: 143-144
7. De Sanctis V, Urso L. Clinical experience with growth hormone treatment in patients with β thalassaemia major. Biodrugs 1999;11:79-85
8. De Sanctis V. Growth and puberty and its management in thalassaemia. Horm Res 2002;58 (Suppl. 1):72-79
9. Soliman AT, El Banna N, Ansari BM. GH response to provocation and circulating IGF-I and IGF-binding protein-3 concentrations, the IGF-I generation test and clinical response to GH therapy in children with β thalassaemia. Eur J Endocrinol 1998;138:394-400
10. Shehadeh N, Hazani A, Rudolf MCJ, Peleg I, Benderly A, Hochberg Z. Neurosecretory dysfunction of growth hormone secretion in thalassaemia major. Acta Paediatr Scand 1990; 79:790-795
11. Postel-Vinay MC, Girot R, Leger J, Hocquette JF, McKelvie P, Amar-Castesec A, Rappaport R. No evidence for a defect in growth hormone binding to liver membranes in thalassaemia major. J Clin Endocrinol Metab 1989;68:94-98
12. Cotterill AM, Camacho-Hubner C, Du Quesnoy P, Savage MO. Changes in serum IGF-I and IGFBP3 concentrations during the IGF-I generation test performed prospectively in children with short stature. Clin Endocrinol 1998;48:719-724